UK markets closed

GH Jul 2024 10.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.21000.0000 (0.00%)
As of 10:34AM EDT. Market open.
Full screen
Previous close0.2100
Open0.2100
Bid0.0000
Ask0.7500
Strike10.00
Expiry date2024-07-19
Day's range0.2100 - 0.2100
Contract rangeN/A
Volume1
Open interest33
  • Benzinga

    What's Going On With Colorectal Cancer Diagnostic-Focused Guardant Health Stock On Tuesday?

    Tuesday, the FDA's staff reviewers raised concerns regarding Guardant Health Inc's (NASDAQ:GH) experimental blood test for colorectal cancer, suggesting it might not detect some tumor types that could become cancerous. Guardant Health is seeking approval for Shield, a blood-based colorectal cancer (CRC) screening test for average-risk adults. Shield is an in vitro diagnostic device intended for the qualitative detection of CRC through sequencing the cell-free DNA (cfDNA) isolated from whole bloo

  • Business Wire

    Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications

    PALO ALTO, Calif., May 21, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced certification for its Guardant360® CDx blood test under the European Union’s In Vitro Diagnostic Regulation (IVDR 2017/746). The certification from TÜV SÜD Product Service is for tumor mutation profiling in patients with any solid cancerous tumor and for companion diagnostic indications to identify patients who may benefit from certain targeted therapies for advanced non-sma

  • Business Wire

    Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    PALO ALTO, Calif., May 17, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 22, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units ("RSUs") representing 215,601 shares of its common stock to 94 new non-executive employees and non-qualified stock option awards to purchase an aggregate of 98,076 shares of its common stock to three new non-executive employees with a grant date